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1. Introduction 
In general, cancer, encompassing prostate cancer (PCa), is a disease that utilises signalling 
pathways to progress through the uncontrolled proliferation of cancerous cells. Although 
the mechanisms of how the cells evade intrinsic or extrinsic signals of death and keep on 
dividing is not completely understood, there is a plethora of evidence that point to certain 
signalling molecules that are crucial conveyors of the fine tuning that slightly differs in 
cancer in comparison to control states. The present chapter provides a detailed description 
of the key regulators of PCa cell life and unveils their closely communicating proteins that 
aid in the fine tuning of the cancerous state. 
2. Androgen receptor (AR) signalling 
A major insight into the potential role of androgens in PCa came almost 70 years ago, from 
the observation that castration of patients with metastatic PCa resulted in a marked 
reduction in the levels of prostate specific antigen (PSA), a PCa serum acid phosphatase 
marker (Huggins and Hodges, 1941). In the same study, injection of androgens in some PCa 
patients resulted in significant increase of PSA. This clearly demonstrated the androgen 
dependency of PCa. The treatment of PCa has been based on inhibition of the synthesis or 
action of the ligand (testosterone and its active metabolite 5-diydrotestosterone (5-DHT)) on 
the androgen receptor (AR). In addition, there are numerous evidence that demonstrate the 
involvement of AR in PCa progression especially castration-recurrent PCa, despite the 
absence of circulating testicular androgens. 
As activation of the AR is associated with induction of proliferation and apoptosis in PCa 
cells, manipulation of androgen-AR relationship such as non steroidal AR antagonists such 
as bicalutamide and flutamide in conjunction with chemical or surgical castration is the 
main therapeutic option available to patients with locally advanced or metastatic cancer. 
However, the AR has been demonstrated to be activated even in castrate conditions, 
independent of testicular androgens. Mechanisms known to be involved with AR 
transactivation are: increased expression of receptor which allows its activation even in low 
levels of andrenal androgens, mutation of AR, non canonical variants of AR, modified 
expression or activity of AR coregulators and cross talk with other pathways regulating 
survival, cell death and proliferation of PCa cells. Usually a combination of these 
mechanisms occur simultaneously to provide PCa cells with an increase in the expression of 
genes that regulate proliferation and apoptosis. 
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Numerous studies, initiated almost a decade ago, are dedicated in unravelling androgen 
regulated gene expression in both normal and tumorgenic prostate cells (please refer to 
review for complete references; Dehm and Tindall, 2006). The majority of large scale studies 
have been performed in LNCaP cells based on their AR-sensitive properties. The number of 
genes regulated by the function of androgens through the AR was recently estimated to be 
between 10,570 and 23,448 polyadenylated RNAs, however this number is set to grow if 
microRNAs are included (Dehm and Tindall, 2006). Furthermore, a recent study utilising a 
microarray analysis of androgen related genes in the cell line LNCaP has demonstrated that 
a large number of genes falling under the regulation of androgens are still of unknown 
function (Ngan et al., 2009). The genes regulated by AR regulate functions of the prostate 
cell related to cell proliferation, cell cycle, survival, death, lipid and steroid metabolism, 
protein products resulting from gene fusions and microRNAs. 
AR signalling that regulates cell proliferation and apoptosis usually arises from cross-talk of 
the pathway with other pathways that are known to regulate these functions. For example, 
the insulin like growth factor-1 (IGF-1) pathway falls under the numerous genes affected by 
the AR-pathway (Schayek et al., 2010). Some of the SMAD and ID proteins involved in the 
transforming growth factor-beta (TGF) pathway are also regulated. Androgens negatively 
regulate the expression of SMAD1, 3, 6 and 7, while ID3 expression is markedly increased 
(Ngan et al., 2009). Some of the forkhead box (FOX) family of transcription factors which are 
important in cell survival are differentially regulated by AR activity (Takayama et al., 2008). 
Furthermore some of the FOX genes can influence AR expression and activity itself. For 
example, FOXP1 has been shown to negatively regulate AR expression (Takayama et al., 
2008). Cyclin D, cdc6 and genes such as UBEC2 are some of the genes regulated by the 
androgenic signalling that control cell cycle checkpoints of PCa cells. In addition, the AR 
signalling can regulate PCa cells apoptosis by regulation of anti-apoptotic molecules such as 
FLIP (Gao et al., 2005; Raclaw et al., 2008). 
Androgens also control the lipid and steroid metabolic pathways that are important in 
providing energy to cells undergoing proliferation. Sterol regulatory element-binding 
proteins (SREBPs), which are responsible for activation of numerous enzymes involved in 
cholesterol processes such as HMG-CoA, acyl CoA:cholesterol acyltransferase (ACAT) are 
regulated by AR (Locke et al., 2008; Leon et al., 2010). 
Recently, reports are exploring the impact of AR signalling in the formation of fusion 
protein arrangements. Androgenic signalling has demonstrated the ability to promote 
interactions of genomic regions and DNA breaks (Lin et al., 2009). 
MicroRNA profiling in the parental hormone naive cell line LNCaP in comparison to 
castrate resistant LNCaP- derived cell line has identified 17 differentially expressed miRNAs 
between the two cells lines (deVere White et al., 2009). In the same study, miR-125b was 
shown to be highly expressed in AR expressing cell lines such as CWR22R, PC-346C, 
LNCaP, cds1 and cds2 cells when in AR negative cell lines (DU145, PC3, pRNS-1-1 and 
RWPE-1) its expression was diminished. These findings suggest that miR-125b may be 
related to prostatic tumorigenesis and androgen independent (AI) growth, and the AR may 
regulate the expression of this miRNA in CaP cells. That notion is further supported by the 
altered expression of miR-125b upon anti-androgen treatment (deVere White et al., 2009).  
There are numerous evidence demonstrating the ability of PCa cells to respond to lower 
levels of androgens due to overexpression of AR protein (Chen et al., 2008). The AR is 
upregulated in most CRPCs, of which only 10–20% exhibit amplification of the AR gene 
www.intechopen.com
 
Signalling Pathways and Gene Expression Profiles in Prostate Cancer 
 
95 
(Edwards et al., 2003), indicating that increased AR expression in CRPC may result from 
factors other than gene amplification such as increased transcription from endogenous 
promoters or from stabilisation of mRNA (Lammond and Tindall, 2010; Shiota et al., 
2011). 
Depletion of androgens during PCa treatment can lead to structural and functional 
changes of AR in the PCa cells in order to adjust and survive in the hormone depleted 
environment (Pienta et al., 2006). Somatic mutations in the ligand binding pocket of the 
ligand binding domain (LBD) of AR are a common feature amongst castrate resistant and 
metastatic prostate tumours, with more than 50% of tumors presented with this type of 
mutations. AR mutations can alter the binding specificity of AR. For example, the 
missense mutation of threonine to alanine at amino acid 877 (T877A) leads to an increase 
in the type of ligands that can bind AR; with estrogens and progesterone having a similar 
binding affinity as androgens in this instance (Montgomery et al., 2001; Han et al., 2005). 
Recently seven more variants have been discovered to be over-expressed in castrate 
resistant PCa (CRPC). Two of these, AR-V1 and AR-V7 that were studied in full detail, 
were shown to possess premature termination codons. High expressions of both variants 
correlated with poor prognosis of patients at CRPC (Hu et al., 2009). The splicing variant 
AR23, that was recently detected in a patient with metastatic CRPC has impaired nuclear 
localisation and increases androgen signalling only in the presence of endogenous wild-
type AR (Jagla et al., 2007). Furthermore this variant has the ability to regulate other 
signalling pathways such as increasing the transcriptional activity of nuclear factor kappa 
B (NFB) and decreasing the activity of activator protein-1 (AP-1). The presence of AR 
variants have been investigated in CRPC cell lines also. AR3, AR4 and AR5 variants were 
identified in C-821, CWR-R1 and CWR22Rv1 cell lines, with AR3 being the most abundant 
variant in these cell lines. AR3 showed both cytoplasmic and nuclear localisation of AR, 
however, AR3 function, activity and expression was not affected by the presence of 
androgens or anti-androgens demonstrating the androgen independence of PCa cells in 
CRPC state. Furthermore, the same study has pinpointed Akt-1 through a microarray 
analysis, as the key difference between the AR and AR3 signalling pathway to drive 
growth of CRPC cells (Guo et al. 2009). Another AR mutation has been identified in the 
CRPC cell line CWR22Rv1 that was absent in the parental hormone naive mimicking cell 
line CWR22. This mutation resulted in the generation of AR protein fragments; one 
characterised by a duplication of exon 3 of AR leading to ARex3dup protein with molecular 
weight of 114kDa, and a second protein ARLBD with a truncated ligand binding domain 
and a lower molecular weight of 75-80kDa (Dehm et al. 2008). Both variants have distinct 
roles in the hormone naive and CRPC states; ARex3dup protein affects the growth of 
hormone naive cells while ARLBD protein affects the growth of castrate resistant cells 
(Tepper et al., 2002). 
3. Heat shock proteins 
Heat shock proteins (Hsps) are a superfamily of proteins produced in cells in response to 
environmental stresses and in particular heat. It is now well established that Hsp70 and 
Hsp90 are bound to the AR when it is held in its inactive form in the cytoplasm. The 
function of the Hsps is to stabilise the receptor and protect it from protelytic degradation. 
However when androgens bind to the AR, Hsp 70 and 90 dissociate, allowing the AR to 
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form homodimers and transolcate to the nucleus. The first evidence that Hsps were 
involved in PCa was obtained almost two decades ago from the direct interaction of the Hsp 
members Hsp90, Hsp70 and Hsp56 with AR (Veldscholte et al., 1992). Furthermore, this 
interaction has been recently verified in a heterologous AR expression system in the 
293HEK cell line. This recapitulates AR SHR activity in PCa cells that identified these 
Hsps as putative AR-binding proteins in the cytosolic extracts using the ICAT method 
(Jasavala et al., 2007). 
Hsps have been implicated in apoptosis and survival of PCa cells as well as response to 
chemotherapeutic treatment. The role of Hsps in these cell processes differs depending on 
the Hsp member involved. The anti-apoptotic role of Hsp70 in PCa, which is known to bind 
to the AR in the inactive state, was demonstrated in vitro by direct transfection of adenoviral 
Ad.asHsp70 in PCa cells such as PC-3 and DU145 cells. The result was impressive, leading 
to cell death of tumorigenic cells within three to five days post-transfection (Nylandsted et 
al., 2000). Increase of Hsp27 and Hsp72 have also been implicated in resistance to apoptotic 
signals in vitro (Gibbons et al., 2000; Garrido et al., 2003). Hsp27 modulates apoptosis 
through prevention of the apoptosome formation and activation of caspases through direct 
sequestration of cytochrome c released from the mitochondria into the cytosol or 
cytochrome c–mediated caspase activation by sequestering both pro-caspase-3 and 
cytochrome c (Bruye et al., 2000, Paul et al., 2000). Also, Hsp27 at high levels may prevent 
the caspase-8 activation of the pro-apoptotic Bid protein, a member Bcl-2 family (Concannon 
et al., 2000). Results from a tissue microarray study on changes in Hsp27 protein expression 
in 232 specimens from hormone naive and posthormone-treated cancers showed that Hsp27 
expression was low or absent in untreated human PCas but increased 4 weeks after 
beginning androgen-ablation to become uniformly highly expressed in AI tumors (Rocchi et 
al., 2004). The same group has evaluated the functional relevance of Hsp27 changes in AI 
progression providing a mechanism by which castration-induced changes in Hsp27 
expression serves as an upstream regulator of Stat3 activity (Rocchi et al., 2005). The 
correlation of the expression of Hsp27, Hsp70 and Hsp90 has also been evaluated in relation 
to clinicopathological outcomes in patients undergoing radical prostatectomy (Kurashami et 
al., 2007). Only Hsp27 expression is significantly associated with pathological stage, Gleason 
score, surgical margin status, lymph node metastasis and tumor volume as well as cell 
proliferative activity. 
4. Src expression 
The Src family encompasses nine non-receptor protein kinases: Src, Fyn, Yes, Blk, Yrk, Fgr, 
Hck, Lck and Lyn with similar structural features. Numerous in vitro studies have shown 
the significance of Src in the development of PCa and its progression to a hormone-
independent state (Slack et al., 2001; Recchia et al., 2003; Nam et al., 2005). In addition, the 
clinical association between Src family kinase (SFK) activity and PCa patient survival 
suggests that SFK activity is up-regulated in a subgroup of CRPC patients (Tatarov et al., 
2009). Furthermore, the same study suggested that an increase in SFK activity in CRPC 
patients may result in higher likelihood of metastatic disease, which could potentially 
contribute to the reduction in survival. 
Extensive cross-talk and co-regulation are two features of the SFK member action. 
Moreover, the Src proline-rich sequences of AR have the affinity for SH3 domain of Src, so 
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that the resulting complexes release Src intramolecular constrains activating the tyrosine 
kinase. Androgen stimulation acts as a trigger for the AR-Src complex formation, which is 
followed by activation of Src/Raf-1/Erk-2 pathway and, as a result, increases in PCa cell 
proliferation. Application of androgen antagonists, expression of Src lacking SH3 domain 
and treatment with Src inhibitor prevented androgen stimulated S-phase entry (Migliaccio 
et al., 2000). A significant correlation between AR and Src activation in human prostate 
tumours has been found with proposed tyrosine Y534 as a Src-specific phosphorylation site. 
Introduction of a dominant negative mutant of Src kinase prevents AR activation and its 
translocation to the nucleus (Lee et al., 2001). These findings suggest that androgen 
deprivation therapy may result in Src activation by growth factors, which can then stimulate 
AR activity as a potential hormone escape mechanism (Guo et al., 2006). Epidermal growth 
factor (EGF) acting through epidermal growth factor receptor (EGFR) has been shown to 
activate Src in PCa cells, experiencing acute androgen withdrawal by triggering AR-Src 
complex formation. Resulting DNA synthesis and cytoskeletal changes were abrogated by 
treatment with androgen antagonists, suggesting that the relationship between AR and Src 
play an important role in PCa cells biology (Migliaccio et al., 2005; Hitosugi et al., 2007). 
Androgen independent growth and cell migration stimulated by Interleukin-8 (IL-8) 
signalling may involve transactivation of AR by Src as application of Src inhibitors and AR 
antagonists significantly inhibited these biological processes (Lee et al., 2004). Interaction 
between IGF system and steroid receptor signalling is thought to play an important role in 
prostatic carcinogenesis, although the precise mechanism of action is not completely 
understood (129;130). Androgens have been shown to up-regulate IGF-1R expression and 
IGF-1-induced Src/MAPK signalling in AR-positive prostate cancer cells (Pandini et al., 
2005). Activation of oestrogen receptor ǃ (ERǃ), known to form complexes with Src and AR 
in prostate cancer cells, can result in similar effect on IGF-1R expression and activation 
(Pandini et al., 2007). 
SFK members are involved in the regulation of focal adhesions, thus playing a key role in 
the regulation of cell motility, migration and invasion. Activation of guanosine phosphate 
binding protein coupled receptors (GPCRs) results in complex formation between Src and 
FAK in focal adhesions, whereas Lyn is thought to inhibit these cellular functions by acting 
as an intermediary between NEP and p85 subunit of PI3-K, preventing association of PI3-K 
and FAK (Sumitomo et al., 2000). Src is thought to be the main factor in tyrosine 
phosphorylation of ezrin, an adaptor protein which is implicated in invasion, migration and 
is important for the development of metastatic PCa (Curto and McClutchey, 2004). 
Application of Src inhibitor PP2 reduced ezrin phosphorylation and decreased invasive 
capacity of androgen stimulated PCa cells (Chuan et al., 2006). Growth factors released into 
the bone microenvironment, including transforming growth factor ǃ (TGFǃ), fibroblast 
growth factor (FGF), IGF, and platelet derived growth factor (PDGF) stimulate Src-mediated 
osteoclast activity, leading to further bone destruction and release of biologically active 
substances from the bone matrix, stimulating the proliferation and migration of tumour cells 
(Araujo and Logothetis, 2009; Edwards, 2010). 
5. PI3K signalling 
Several key components of the PI3K/Akt cascade have been implemented in prostate 
carcinogenesis and castration resistance. PI3K inhibition has been studied in vitro for some 
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time and evidence of its key role in carcinogenesis continue to emerge. Genetic analysis of 
high Gleason grade PCas revealed 3% of patients had PIK3CA mutation and 13% had 
PIK3CA amplification (Sun et al., 2009). Up regulation of PI3K signalling may also be due to 
overexpression of receptor tyrosine kinases (RTKs) which have been previously reported to 
be overexpressed in prostate tumours and cell lines (Grasso et al., 1997; Yeh et al., 1999; 
Barlett et al., 2005). PI3K has shown to be an important signalling molecule and key survival 
factor involved in PCa proliferation and invasion. Studies have reported that treatment of 
LNCaP, PC-3 and DU145 with PI3K pharmacological inhibitor, LY294002, potently 
suppresses the invasive properties in each of these cell lines and restoration of the PTEN 
gene to highly invasive prostate cancer PC-3 cells or expression of a dominant negative 
version of Akt also significantly inhibites invasion and down regulates protein expression of 
urokinase type plasminogen activator (uPA) and matrix metalloproteinase (MMP)-9, 
markers for cell invasion. Increased levels of PI3K (p110) and regulatory (p85) and Akt were 
also observed in these cell lines (Shukla et al., 2007). 
A somatic mutation in AKT1 (E17K) has been detected in numerous cancers including 
prostate (Bleeker et al., 2008; Boorman et al., 2010). The E17K substitution leads to a PI3K 
independent activation of AKT1. In PCa, AKT1 mutation was reported to have a prevalence 
of just 1.4% and the mutation seemed to be associated with favourable clinical outcome and 
was not associated with a specific tumour growth pattern (Boormans et al., 2010). 
Overexpression of Akt in PCa is hypothesised to be due to defective PTEN gene as 
discussed below. Prostate tumours are reported to have significantly higher Akt expression 
than BPH (Liao et al., 2003), and only 10% of well-differentiated prostate tumours strongly 
express pAkt compared to 92% of poorly differentiated tumours (Malik et al., 2002; Ayala et 
al., 2004). Additionally, in hormone-naive tumours Akt1 and Akt2 expression has been 
associated with shorter time to biochemical relapse; and amplification was observed in 
castrate resistant tumours (Kirkegaard et al., 2010). In addition phosphorylation of Akt 
increases with the development of castrate resistant disease and is associated with reduced 
disease specific survival (McCall et al. 2008; Edwards et al., 2006). Loss of PTEN has been 
associated with advanced prostate cancer (Gray et al., 1998) and loss of PTEN expression is 
associated with increased risk of recurrence in human tumours (McMennin et al., 1999, 
McCall et al., 2008). 
PCa cell lines that have been cultured from metastatic sites such as the lymph nodes 
(LNCaP) or brain metastasis (PC3) have highly active PI3K/Akt signalling and PTEN 
deletion (Davies et al., 1999; Murillo et al., 2001) The magnitude of loss of function of PTEN 
is best described in both localised and metastatic PCas and includes homozygous deletions, 
loss of heterozygosity (LOH) and inactivating mutations (Sarker et al., 2009). The reported 
frequency and mode of inactivation at different stages of PCa varies. Homozygous deletions 
of PTEN have been detected in up to 15% of locally confined PCa and up to 30% in 
metastatic cases (Verhagen et al., 2006; Yoshimoto et al., 2007). Heterozygous loss has been 
reported in 13% of locally confined prostate cancers and up to 39% in metastatic cases 
(Samuels et al., 2004; Verhagen et al., 2006; Yoshimoto et al., 2007). PTEN mutation has been 
associated with 5-27% of localised and 30-60% of metastatic prostate tumours (Feiloter et al., 
1998; Suzuki et al., 1998) In addition, loss of PTEN expression is associated with disease 
progression and increased risk of recurrence (Fenci et al., 2002) although substantial 
heterogeneity has been observed between different metastatic sites within the same patients 
(Suzuki et al., 1998). 
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Many oncoproteins and tumor suppressors intersect in the PI3K cascade, regulating 
cellular functions at the interface of signal transduction and classical metabolic regulation. 
This careful balance is altered in human cancer by a variety of activating and inactivating 
mechanisms that target both Akt and interrelated proteins. Numerous studies have 
suggested that PI3K signalling enhances its oncogenic signal through interaction with 
other signalling networks such as the transcription factor Nuclear factor Kappa B (NFB) 
(Romashkova and Makarov, 1999). Recent reports suggest that suppression of NFB 
activity by inhibitory kappa B (IκB) superepressor induces a strong and selective 
resistance to PI3K or Akt induced oncogenic transformation which suggests an essential 
role for NFB in the transforming mechanisms induced by this signalling cascade (Bai et 
al., 2009).  
6. NFB signalling 
NFκB has been shown to be constitutively activated in PCa cells. Evidence on the direct 
involvement of NFκB in the regulation of angiogenesis and metastasis of PCa cells have 
already been obtained. Suppression of NFκB activity in human PCa cells by inhibitory kappa B 
alpha (IκBǂ) mutation transfection inhibits their tumorigenic and metastatic properties in nude 
mice by suppressing angiogenesis and invasion. In the same experiments, IκBǂM transfection-
blocked NFκB activity was associated with downregulation of several angiogenic genes such 
as vascular endothelial growth factor (VEGF), interleukin 8 (IL-8) and matrix metalloprotease-
9 (MMP-9) in cultured cells and in cells implanted into the prostate gland of nude mice. The 
decreased expression of VEGF, IL-8 and MMP-9 in vivo directly correlated with decreased 
neovascularization and production of lymph node metastasis. In addition, direct clinical 
correlations of the expression levels the angiogenic genes, including VEGF, basic fibroblast 
growth factor (Bfgf), IL-8 and MMP-2 and MMP-9 with the metastatic potential of PCa cells 
has already been established (Huang et al., 2002;Andela et al., 2003). 
The association between steroid hormone receptor expression and NFκB activation has been of 
substantial interest in prostate cancer. Prominent constitutive NFκB has been observed in the 
prostate cancer cell lines PC-3 and DU-145 which lack AR expression however, only very low 
levels of NFκB were seen in the AR positive cell line LNCaP (Suh et al., 2002). Moreover, a 
markedly higher NFκB activity in an androgen independent prostate cancer xenograft model 
than in its androgen dependent counterpart (Chen et al., 2002). Here NFκB activated 
expression of AR regulated gene PSA. This data may suggest that either the presence of AR 
actually inhibits NFκB activity in prostate cancer or alternatively that constitutive activation of 
NFκB may correlate with AR loss, which in turn may contribute to compensatory cellular 
changes, allowing cell survival and growth in the absence of AR activation.  
NFκB has been implicated with PCa progression via two mechanisms, promotion of 
metastases via MMP-9 expression or promotion of androgen independence via an as yet 
unknown mechanism. It was suggested that the absence of PTEN might contribute to 
constitutive activation of NFκB induced by PI3K/Akt pathway. However no direct 
correlation has been observed in prostate cancer cell lines.  
7. Bcl-2 signalling 
Bcl-2 family plays a central role in the mitochondrial pathway of apoptosis by regulation of 
the integrity of the outer membranes of mitochondria. Members of this family have different 
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role in apoptosis; Bcl-2, Bcl-xL, Bcl-w, A1, and Mcl-1 members are considered as anti-
apoptotic molecules while Bax, Bak, and Bok have pro-apoptotic functions and Bad, Bim, 
Bid, Puma, and Noxa control the activation of pro-apoptotic proteins. 
In PCa, Bcl-2 expression is correlated with a higher Gleason score and pT category and is 
lower in localized PCa compared with HRPC change to CRPC (McDonnell et al., 1992; 
Apakama et al., 1992; Bubendorf et al., 1996). It has been reported that high expression of 
Bcl-2 may enable the PCa cells to survive in an androgen-deprived environment, and to 
confer resistance to anti-androgen therapy (McDonnell et al., 1992). On the other hand, 
Bak and Bax expression is significantly higher in localized PCa than in HRPC. In addition, 
decreased Bax expression is associated with an increased pre-operative PSA level in 
localized PCa and early disease progression in HRPC (Yoshino et al., 2006). These 
findings suggest that differential regulation of anti-apoptotic Bcl-2 protein and pro-
apoptotic proteins may be involved with the processes controlling the development of 
HRPC as well as disease progression in PCa (Yoshino et al., 2006). In vitro, Bax and Bcl-X 
overexpression resulted in apoptotic cell death in PCa cells such as PC3 and DU145, 
which are known to offer resistance to a variety of chemical proapoptotic agents as well as 
LNCaP cells (Marcelli et al., 2000; Li et al., 2001; Castilla et al., 2006). Bcl-X expression is 
observed in all tumours and was generally stronger in high grade primary tumors (grade 
8 to 10) and metastases compared with PIN and low grade neoplasms (P < 0.0001) 
(Krajewska M et al., 1996; Castilla et al., 2006). On the other hand, a recent study in a 58 
patient cohort of PCa patients aith matched tissue from androgen-dependent to CRPC 
tumours, showed that there was a trend with improved overall survival in patients with 
increased Bad expression at diagnosis. 
In addition, there were trends towards a decrease in Bad and Bax expression with disease 
progression (Teo et al., 2007). These results might signify that Bad expression may represent 
a possible positive prognostic marker and useful therapeutic target in HRPC management in 
the future. 
8. IL-6R/STAT3 
The IL-6R/gp130/JAK/STAT3 pathway is also implicated in the development of PCa. It is 
known that circulating levels of IL-6 in sera of patients with CRPC are elevated in 
comparison to hormone naive patients (Hobisch et al., 1998; Drachenberg et al., 1999). The 
initial hypothesis of cross-talk between IL-6 and the AR, by measuring the effects of IL-6 
on AR transcriptional activity, was investigated in two cell lines, DU-145 which 
transiently expresses the AR and LNCaP which contains a promiscuous mutated AR. In 
both cell lines IL-6 activated the AR in a ligand-independent and synergistic manner with 
low concentrations of a synthetic androgen (methyltrienolone) (Hobisch et al., 1998). 
Later, Yang et al (2003) was to demonstrate that IL-6, enhanced AR transactivation via IL-
6R/STAT3 pathway. Lee et al (2004) observed that androgen sensitive LNCaP cells in the 
presence of IL-6 were protected from apoptosis when deprived of androgen. However, 
the anti-apoptotic activity of IL-6 was prevented by the expression of a dominant-negative 
STAT3 mutant, STAT3F. Furthermore, androgen deprivation induced LNCaP cell death 
which was antagonized by ectopic expression of a constitutively active STAT3 (Lee et al., 
2004). DeMiguel et al (2002) has demonstrated that constitutive activation of STAT3 is 
associated with increased cell growth and prolonged survival in androgen sensitive 
LNCaP cells. The study was extended to involve in vivo work using both intact and 
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castrated nude male mice. Activation of STAT3 resulted in an increase in tumour growth 
in both groups of mice. This study shows that STAT3 can enhance the growth of hormone 
sensitive tumour even in low circulating androgen conditions in vivo. More in vivo work 
demonstrated that constitutive activation of STAT3 was found in 82% of human prostate 
tumours as compared with matched adjacent non-tumour prostate tissue in radical 
prostatectomy samples (Edwards et al., 2005). Furthermore higher levels of STAT3 
activation correlated with a more aggressive tumour or a higher Gleason score. In 
addition to this, three prostate cancer cell lines, DU145, PC3 and LNCaP cells were 
examined all of which displayed constitutive activation of STAT3, though substantially 
lower levels of STAT3 activation was observed in hormone sensitive LNCaP cells. This 
further supports the fact that STAT3 activation is involved in the progression of prostate 
cancer. The fact that activated STAT3 is found in tumour and not around its normal 
margins of prostatectomy samples was further supported by Barton et al (2004). In 
addition they also showed that directly inhibiting STAT3 either using antisense STAT3 
oligonucleotides or by transfecting cells with a dominant negative (DN) STAT3 plasmid, 
resulted in apoptosis. Cell lines used were NRP-154 and DU145 and apoptosis was seen in 
both lines when inhibition of STAT3 was performed. From these data the authors 
conclude that STAT3 specific inhibitors could be used in treating CRPC. Similar 
conclusions were drawn by (Tam et al, 2007) who reported that cytoplasmic pSTAT3Tyr 705 
expression is associated with time to death from hormone relapse and disease specific 
survival of the prostate cancer patients that develop castrate resistant disease. 
9. Mitogen activated protein (MAP) kinase pathway 
Alterations to members of the Raf/MAP kinase pathway have been linked with the 
progression of several solid tumours including prostate cancer (Weinstein-Oppenheimer 
et al., 2000). Most solid tumours demonstrate a link between Ras mutation and MAP 
Kinase activation (Edwards et al., 2004). Mutated Ras has been linked with increased 
levels of activated MAP Kinase and the development of androgen-independent growth in 
LNCaP cells (Bakin et al., 2003; Edwards et al., 2004). Activated MAP Kinase and MEK are 
also differentially expressed during the progression of prostate cancer in a transgenic 
mouse model (Uzgare et al., 2003-as referenced in Edwards et al., 2004). Raf and MEK are 
known to be expressed in both non-metastatic and metastatic prostate cancer cells 
(Weinstein-Oppenheimer et al., 2000; Fu et al., 2003). Increased MAP Kinase activity is 
known to be elevated in androgen insensitive cell-lines and in clinical CRPC (Abreu-
Martin et al., 1999; Gioeli et al., 1999). Recently increasing levels of Raf-1 and/or MAPK 
correlated with a more rapid biochemical relapse and rapid decline into CRPC, thus 
negatively impacting on survival time (Mukherjee et al., 2011). Intriguingly, the 
constitutively active form of MAP Kinase also induces Raf-1 activation in cell-line studies, 
forming the positive feedback loop required for chronic autocrine stimulation 
(Allessandrini et al., 1997; Weinstein-Oppenheimer et al., 2000). MAP Kinase has also been 
demonstrated to increase transcription of androgen-dependent genes, independently of 
androgens, via either direct or indirect phosphorylation of the AR (Abreu-Martin et al., 
1999; Bakin et al., 2003; Franco et al., 2003). MAP Kinase is known to activate the AR N 
terminal domain (NTD) by phosphorylation of the serine 515 site independently of 
androgen (Yeh et al. 1999; Rochette-Egly, 2003). Inhibition of MAP Kinase in cell-line 
studies is known to abrogate IL-6 and PKA activation of the AR, suggesting a crucial role 
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in the convergence of both pathways towards the AR NTD (Ueda et al., 2002). 
Hydroxyflutamide has been shown to activate the Raf/MAP Kinase pathway 
independently stimulating cell proliferation, possibly via a member of the EGFR receptor 
family (Lee et al., 2002). Activation of the pathway has therefore been linked with the 
pathogenesis of the androgen-withdrawal syndrome, by stimulating androgen-
independent cell growth in response to antiandrogens. Data has also revealed increased 
activation of the MAP Kinase pathway in prostate cancer in patients with tumour 
progression (Gioeli et al., 1999; Lee et al. 2002). Taken together, the MAP Kinase pathway 
appears to play a crucial role in cross-talking with the AR-signalling pathway, modulating 
its response to ligands. It may also function as a surrogate for ligand-activation during 
androgen withdrawal, resulting in the progression to CRPC. 
10. Human epidermal growth factor receptor (her) signalling 
The Human Epidermal Growth Factor Receptor (HER) family consists of 4 
transmembrane glycoprotein receptor molecules and their variants; Epidermal Growth 
Factor Receptor (EGFR also known as HER1 and ErbB1), HER2 (ErbB2), HER3 (ErbB3) 
and HER4 (ErbB4). The HER family members are all differentially expressed in malignant 
compared to benign prostatic tissue. Great variability of EGFR has been reported amongst 
studies, with 17-100% detactable levels observed (Di Lorenzo et al., 2002) which has been 
attributed mainly in PCa disease heterogeneity amongst tissue specimens and variation in 
IHC technique procedures (Hernes et al., 2004). EGFR overexpression both at the protein 
and transcript level has been reported in metastatic PCa in numerous studies (Kumar et 
al., 1996, Kim et al., 1999). Furthermore, the expression of EGFR variant EGFRvII has only 
been detected in PCa cells and not in benign prostate tissue. In addition EGFRvII 
expression is greater in CRPC samples compared to hormone naive tissue (Olepade and 
Oleopa, 2001). Contradictory is also the expression of HER2 in studies in patient tissue; 
some studies have noted greater expression of HER2 in PCa than benign tissue (Hernes et 
al., 2004; Okegawa et al., 2006) while others demonstrated no significant difference 
between the two states (Mellon et al., 1992). In general, HER2 expression in PCa is lower 
than other tumor types (Edwards, 2003). Furthermore, HER2 gene amplification is not a 
feature of the transition of hormone naive PCa to CRPC (Bartlett et al., 2005). HER3 is 
consistently expressed in PCa tissue, however, only nuclear expression and not 
cytoplasmic is significantly different from benign tissue (Koumakpayi et al., 2006). On the 
other hand, HER4 is expressed at low levels in PCa tissue and its expression in CRPC 
samples may offer up to 2 years survival (Hernes et al., 2004). This is contradictory to 
HER1-3 expression which is associated with worse prognosis. Heregulins are highly 
expressed in benign prostate tissue compared to malignant (prostatectomy derived PCa) 
(Lyne et al., 1998). This may indicate that HRGs may act as tumor suppressors and its loss 
might signify an early stage in PCa oncogenesis. 
HER role in prostate carcinogenesis relies in cross-talk interactions with other pathways. 
EGFR member can cross-talk with the signalling pathways of P13K/Akt, MAP kinase and 
PKC to increase growth, modulate cell cycle progression, cell motility and angiogenesis of 
CaP oncogenesis (Mimeault et al., 2003). Overexpression of the EGFR-HER2 heterodimer 
in comparison to other HER dimers is considered an alternative mechanism of HER-
induced carcinogenesis (Xia et al., 1999). EGFR activity has been implicated in hormone 
escape. EGFR signalling has been shown to activate AR in the absence of adrogenic 
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stimulation (Mimeault, 2003). Cross-talk between HER2 and AR pathways is also 
apparent (Mellinghoff et al., 2004; Yeh et al., 1999). HER2 and HER3 expression, 
stimulated by HRG, have also been shown to increase AR transactivation and tumour 
proliferation in a recurrent CaP cell line in the absence of androgen (Gregory et al., 2005). 
Overexpression of HER2 has been shown to be induced by low androgen environments in 
vitro and in vivo (Berger et al., 2006). Androgen independent AR transactivation can be 
induced by spontaneous HER2 homodimerisation in the presence of extreme 
overexpression of HER2 (Wen et al., 2000). In vitro, the Q646C constitutively active HER4 
mutant inhibits formation of colonies in DU-145 and PC-3 CaP cell lines suggesting that 
the HER4 signalling is coupled to PCa cell growth arrest and tumor suppression (Williams 
et al., 2003). 
11. Fibroblast growth factor (FGF) receptor signalling 
FGF functions are mediated through high ligand-specific affinity receptor signalling. FGF 
receptor overexpression has been evident in malignant PCa biopsies of patients. In 
particular, FGFR1 and FGFR4 receptor expression at protein and transcript level are 
significantly upregulated compared to benign prostates (Sahadevan et al., 2007). 
Furthermore, FGFR1 is involved in PCa initiation (Acevedo et al., 2007) and promotes 
tumour progression (Feng et al. 1997). Transgenic models that express constitutively active 
FGFR-1 in the prostate epithelium develop hyperplasia and PIN (Wang et al. 2002, 2004a) 
and increased expression accelerates the appearance of this phenotype (Jin et al. 2003; 
Kwabi-Addo et al., 2004). The role of FGFR2 in prostate cancer is dependent on the 
expression of its specific isoform (Kwabi-Addo et al., 2001). More specifically, increased 
expression of FGFR2IIIc isoform and not of FGFR2IIIb was observed in only in a subset of 
PCa tissue compared to normal epithelial cells. No significant change in the levels of FGFR3 
expression and cellular localisation is observed in both benign prostatic hyperplasia (BPH) 
and PCa tissue (Gowardhan et al., 2005). Increased FGFR4 expression and the germline 
FGFR4 Gly388Arg polymorphism is associated with adverse survival of patients with PCa 
(Wang et al. 2004; Gowardhan et al., 2005; Murphy et al., 2010). Moreover, the presence of 
the FGFR4 GlyArg388 polymorphism is correlated with the occurrence of pelvic lymph 
node metastasis and PSA recurrence in men undergoing radical prostatectomy. Expression 
of the FGFR-4 Arg388 in immortalized PCa epithelial cells results in increased cell motility 
and invasion and upregulation of the urokinase-type plasminogen activator receptor 
(uPAR), which is known to promote invasion and metastasis (Sidenius & Blasi, 2003; Kwabi-
Addo et al., 2004). 
In PCa, upregulation of some ligands of the FGF system has also been reported; FGF1, 
FGF2, FGF6, FGF8, FGF10 and FGF17 mainly used as autocrine or paracrine factors for 
PCa cells (Heer et al., 2004; Kwabi et al., 2004). FGF1 is known to be expressed in more 
than 80% of PCa (Dorkins et al., 1999) and be increased in PIN. FGF1 was shown to induce 
the expression of matrix metalloproteinase MT1-MMP which is also overexpressed in PIN 
and invasive cancers and might provide a link to the role of FGF1 in the progression of 
PCa (Udayakumar et al., 2004). FGF2 expression is altered during the progression of PCa; 
evidence shows that paracrine stromal expression can be observed during early stages of 
PCa which eventually switches to autocrine expression by epithelial cells (Dorkin et al., 
1999; Girri and Ittmann, 2001). FGF1 and FGF2 regulate angiogenesis. In particular, 
expression of FGF2 in PCa cells and stromal cells can induce tumour vasculature 
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formation (Powers et al., 2000; Kwabi-Addo et al., 2004). FGF6 is expressed by normal 
prostatic basal cells in extremely small amounts, and expression in basal cells is markedly 
increased in PIN lesions. The acquisition of FGF6 expression by the prostate cancers 
implies but does not prove that it may play a role in cancer cell proliferation or perhaps in 
other aspects of tumor progression (Ropiquet et al., 2000). The role of FGF7 still remains 
unclear although it was one of the first factors shown to regulate AR transcription in PCa 
cells, along with EGF and IGF-I (Culig et al.,1994). Recent evidence support the role of 
paracrine mesenchymal FGF10 in driving tumourgenesis as enhanced expression of 
mesenchymal FGF10 was sufficient for histologic transformation of the adjacent prostate 
epithelium in CB.17SCID/SCID mice (Memarzadeh et al., 2007). FGFs play an important role 
in all stages of bone formation. Thus, it is not surprising that some FGF members have 
been linked with bone metastasis of PCa. FGF8 secreted by cancer cells regulates 
osteoblast differentiation by enhancing osteoprogenitor cell proliferation and their 
osteogenic capacity (Valta et al., 2006). Moreover, FGF8 in particular is expressed highly 
in PCa bone metastasis and was recently shown to increase the growth of intratibial PC3 
tumors in nude mice used as an experimental model for PCa bone metastasis (Valta et al., 
2008). FGF8 can also induce FGF17 expression which has also been associated with bone 
metastasis (Heer et al., 2004). 
12. Insulin growth factor receptor (igfr) signalling 
The insulin-like growth factor (IGF) system, is composed of the receptors IGFR-IR, IGFR-IIR, 
insulin receptor (IR), numerous atypical receptors, two ligands (IGF-I and IGF-II), and six 
binding proteins (IGFBP-1 to -6) (Nakae et al., 2001). Involvement of the IGF system in the 
progression of hormone naïve PCa to CRPC and metastasis of PCa tumour has had a long 
standing role, and along with androgens and EGF, IGFs represent another important class of 
mitogens in PCa. Early in vitro work has shown that treatment with IGF-I and IGF-II can 
increase the proliferation of PCa DU145 cells (Connolly and Rose, 1994). However, in 
LNCaP cells, IGF-I alone was unable to increase cell growth in growth factor free conditions, 
revealing the need of IGF signalling for co-operation with other factors in order to promote 
tumour cell growth (Ngo et al., 2003). Although most of the members of the IGF system are 
expressed in PCa patients the results from numerous studies are fairly contradictory. 
Studies on the IGF-I serum levels and PCa risk have shown mixed results with some studies 
showing a positive correlation while others showing no or inverse correlation. Furthermore 
similar associations were produced for IGFBP3 and PCa. A large study from the Cancer 
Research UK Epidemiology Unit in 2007 examining 630 specimens from PCa patients at 
diagnosis and 630 matched control samples, did not identify a strong correlation between 
serum IGF-I neither IGFBP3 and PCa risk and only a small increase in risk was noted for 
advanced stage disease. 
Significant interactions of IGF-I have been reported with AR, depicting a significant 
involvement of this pathway in CRPC. In vitro experiments in M12AR cells showed that 
IGF-I enhances nuclear translocation of AR in the absence of any androgenic signal and this 
effect can be inversed by an IGF-IR inhibitory antibody (Wu et al., 2006). In vitro studies 
have demonstrated that IGF-1R downstream signalling via MAPK pathway may promote 
proliferation of prostate cancer cells whereas involvement of PI3K-AKT pathway is required 
to inhibit apoptosis (Genningens et al., 2006). 
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IGF-I plays an important role in PCa bone metastasis. IGF-I can cross-talk with the NFB 
pathway by direct upregulation of RANK ligand and osteoblasts and binding to RANK. 
Activation of NFB leads to osteoclast synthesis and osteoprotegerin (OPG) thus driving 
bone formation and resorption (Fizzazi et al., 2003). 
13. Conclusion 
The signalling pathways involved in the initiation and progression of PCa are complex 
and require further investigation. However in this chapter we have attempted to elucidate 
which receptors (HER, FGFR and IGFR) and intracellular signalling pathways play major 
roles in prostate cancer. In addtion, we also demonstrate that the AR has a central role to 
play in both hormone naïve and castrate resistant disease, and it is only by unravelling 
the interactions between cell surface receptors, intracellular signalling and steroid 
receptors that we are going to move forward with a targeted personalised approach to 
treatment of PCa. 
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